Previous 10 | Next 10 |
home / stock / nvs / nvs articles
Wednesday, Novartis AG (NYSE:NVS) reported fourth-quarter 2023 net sales of $11.42 billion, up 8% (up 10% at constant currency,...
Disappointing tech tidings appear to be weighing down on the market, with the Nasdaq futures diving in early trading on Wednesday while the Dow fut...
U.S. stock futures were mostly lower this morning, with the Nasdaq futures falling more than 200 points on Wednesday. Shares of Alphabet Inc. (NAS...
Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the ...
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell ca...
Thursday, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics Inc (NASDAQ:CYTK) acquisition, dealin...
Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow ...
Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. What To Know: Cytokinetics stock ...
Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). T...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...